Cwm LLC Increases Position in Sarepta Therapeutics, Inc. $SRPT

Cwm LLC boosted its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 4,033.3% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 72,705 shares of the biotechnology company’s stock after purchasing an additional 70,946 shares during the quarter. Cwm LLC’s holdings in Sarepta Therapeutics were worth $1,401,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Ancora Advisors LLC increased its position in shares of Sarepta Therapeutics by 150.0% in the first quarter. Ancora Advisors LLC now owns 500 shares of the biotechnology company’s stock valued at $32,000 after buying an additional 300 shares in the last quarter. Public Employees Retirement System of Ohio grew its stake in Sarepta Therapeutics by 2.2% in the 2nd quarter. Public Employees Retirement System of Ohio now owns 28,792 shares of the biotechnology company’s stock valued at $492,000 after acquiring an additional 607 shares during the period. State of Michigan Retirement System grew its stake in Sarepta Therapeutics by 3.1% in the 2nd quarter. State of Michigan Retirement System now owns 23,600 shares of the biotechnology company’s stock valued at $404,000 after acquiring an additional 700 shares during the period. Thrivent Financial for Lutherans increased its holdings in Sarepta Therapeutics by 3.3% in the 2nd quarter. Thrivent Financial for Lutherans now owns 23,140 shares of the biotechnology company’s stock worth $396,000 after acquiring an additional 744 shares in the last quarter. Finally, Vident Advisory LLC raised its position in Sarepta Therapeutics by 27.8% during the first quarter. Vident Advisory LLC now owns 3,748 shares of the biotechnology company’s stock worth $239,000 after acquiring an additional 815 shares during the period. 86.68% of the stock is owned by institutional investors and hedge funds.

Sarepta Therapeutics Stock Down 1.0%

Shares of SRPT opened at $21.31 on Monday. Sarepta Therapeutics, Inc. has a 52-week low of $10.41 and a 52-week high of $129.84. The company has a quick ratio of 1.79, a current ratio of 2.95 and a debt-to-equity ratio of 0.78. The stock has a fifty day simple moving average of $20.61 and a two-hundred day simple moving average of $19.43. The company has a market capitalization of $2.23 billion, a PE ratio of -7.08, a price-to-earnings-growth ratio of 0.46 and a beta of 0.48.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings data on Monday, November 3rd. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.15). Sarepta Therapeutics had a negative net margin of 11.25% and a negative return on equity of 4.85%. The firm had revenue of $399.36 million during the quarter, compared to analysts’ expectations of $331.51 million. During the same period in the prior year, the company posted $0.62 EPS. The company’s revenue for the quarter was down 14.5% compared to the same quarter last year. As a group, equities analysts forecast that Sarepta Therapeutics, Inc. will post 2.67 EPS for the current year.

Wall Street Analysts Forecast Growth

SRPT has been the topic of several recent analyst reports. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Sarepta Therapeutics in a report on Monday, December 29th. Piper Sandler upped their price target on shares of Sarepta Therapeutics from $15.00 to $16.00 and gave the stock a “neutral” rating in a research report on Thursday, October 30th. Wedbush assumed coverage on shares of Sarepta Therapeutics in a research note on Tuesday, December 9th. They issued an “outperform” rating and a $32.00 price target on the stock. Mizuho upgraded Sarepta Therapeutics from a “neutral” rating to an “outperform” rating and boosted their price objective for the stock from $19.00 to $26.00 in a research note on Wednesday, November 5th. Finally, Wall Street Zen cut Sarepta Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, November 8th. Nine investment analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and six have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $33.68.

Insider Buying and Selling at Sarepta Therapeutics

In other news, COO Ian Michael Estepan sold 13,187 shares of the firm’s stock in a transaction that occurred on Tuesday, December 16th. The shares were sold at an average price of $22.31, for a total transaction of $294,201.97. Following the completion of the sale, the chief operating officer owned 193,300 shares in the company, valued at $4,312,523. This trade represents a 6.39% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 7.60% of the stock is currently owned by company insiders.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.